Gunderson Dettmer Advises Tarsus Pharmaceuticals on Upsized Underwritten Public Offering

Gunderson Dettmer represented client Tarsus Pharmaceuticals, a biopharmaceutical company, in its March 2025 upsized underwritten public offering of 3,230,336 shares of its common stock at a public offering price of $44.50 per share, including the exercise in full of the underwriters option to purchase additional shares. The net proceeds from the offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $134.8 million. Tarsus Pharmaceuticals applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. acted as joint book-running managers for the offering.

The Gunderson Dettmer deal team was led by Ryan Gunderson and Andy Thorpe and included Leanne Gould and Amanda Sharp.

Companies
Tarsus Pharmaceuticals
Goldman Sachs & Co. LLC
BofA Securities
Barclays
Oppenheimer & Co.